Skip to main content

A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership

Start Date

January 1, 2015

End Date

December 31, 2022
 

Administered By

Duke Cancer Institute

Awarded By

The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership

Start Date

January 1, 2015

End Date

December 31, 2022